Front Matter
Show Items
Solution/Suspension/Syrup
Acetazolamide Suspension 25 mg/mL—Formulation 2
Acetylcysteine Solution 10 mg/mL
Acetylcysteine Solution 100 mg/mL
Allopurinol Suspension 20 mg/mL—Formulation 1
Allopurinol Suspension 20 mg/mL—Formulation 2
Amiodarone Hydrochloride Suspension 5 mg/mL—Formulation 1*
Amiodarone Hydrochloride Suspension 5 mg/mL—Formulation 2
Amitriptyline Hydrochloride Suspension 10 mg/mL
Amitriptyline Hydrochloride Suspension 20 mg/mL
Amitriptyline Hydrochloride Syrup 1 mg/mL
Amphetamine and Dextroamphetamine (Adderall) Suspension 1 mg/mL
Atenolol Suspension 1 mg/mL
Atenolol Suspension 5 mg/mL
Atenolol Syrup 2 mg/mL—Formulation 1*
Atenolol Syrup 2 mg/mL—Formulation 2*
Atropine Sulfate Suspension 0.1 mg/mL
Azathioprine Suspension 50 mg/mL
Benazepril Hydrochloride Suspension 2 mg/mL
Bethanechol Chloride Solution 1 mg/mL
Bethanechol Chloride Suspension 5 mg/mL*
Buspirone Hydrochloride Syrup 2.5 mg/mL
Busulfan Syrup 2 mg/mL
Candesartan Cilexetil Suspension 1 mg/mL
Captopril Solution 1 mg/mL*
Captopril Suspension 0.75 mg/mL
Captopril Suspension 0.8 mg/mL
Captopril Suspension 1 mg/mL
Carvedilol Suspension 0.1 mg/mL
Carvedilol Suspension 1.67 mg/mL
Carvedilol Suspension 5 mg/mL
Celecoxib Suspension 10 mg/mL—Formulation 1
Celecoxib Suspension 10 mg/mL—Formulation 2
Chloroquine Phosphate Suspension 15 mg/mL—Formulation 1
Chloroquine Phosphate Suspension 15 mg/mL—Formulation 2
Chloroquine Phosphate Syrup 16.7 mg/mL*
Chlorpromazine Hydrochloride Syrup 100 mg/mL
Cinacalcet Suspension 5 mg/mL
Clonazepam Suspension 0.1 mg/mL
Clonazepam Suspension 0.2 mg/mL
Clonidine Hydrochloride Suspension 0.01 mg/mL
Clonidine Hydrochloride Syrup 0.02 mg/mL*
Clonidine Hydrochloride Syrup 0.1 mg/mL
Clopidogrel Bisulfate Suspension 5 mg/mL
Codeine Phosphate Syrup 3 mg/mL
Cyclophosphamide Suspension 10 mg/mL
Dantrolene Sodium Syrup 5 mg/mL
Dapsone Suspension 2 mg/mL—Formulation 1
Dapsone Suspension 2 mg/mL—Formulation 2
Dapsone Syrup 2 mg/mL
Diclofenac Sodium Suspension 5 mg/mL
Diltiazem Hydrochloride Suspension 12 mg/mL
Diltiazem Suspension 12 mg/mL
Dipyridamole Suspension 10 mg/mL—Formulation 1
Dipyridamole Suspension 10 mg/mL—Formulation 2
Disopyramide Syrup 1 mg/mL
Disopyramide Syrup 10 mg/mL
Dolasetron Mesylate Suspension 10 mg/mL
Erlotinib Suspension 10 mg/mL
Eslicarbazepine Acetate Suspension 40 mg/mL
Ethacrynic Acid Solution 1 mg/mL
Etoposide Solution 10 mg/mL
Flecainide Acetate Suspension 20 mg/mL—Formulation 1*
Flecainide Acetate Suspension 20 mg/mL—Formulation 2
Flucytosine Suspension 10 mg/mL
Flucytosine Suspension 50 mg/mL*
Glutamine Suspension 250 mg/mL
Granisetron Hydrochloride Suspension 0.05 mg/mL
Granisetron Hydrochloride Syrup 0.2 mg/mL
Hydralazine Hydrochloride Suspension 4 mg/mL*
Hydrochlorothiazide Suspension 2 mg/mL
Hydrocortisone Hemisuccinate Suspension 2 mg/mL
Hydrocortisone Sodium Phosphate Suspension 2 mg/mL
Hydrocortisone Suspension 1 mg/mL—Formulation 1
Hydrocortisone Suspension 1 mg/mL—Formulation 2
Hydrocortisone Suspension 2 mg/mL*
Hydroxychloroquine Sulfate Suspension 25 mg/mL
Hydroxyurea Syrup 100 mg/mL*
Hypromellose Suspension 10 mg/mL
Imatinib Syrup 40 mg/mL
Imipramine Hydrochloride Suspension 5 mg/mL
Indinavir Liquid 10 mg/mL
Isradipine Syrup 1 mg/mL
Ketoconazole Suspension 20 mg/mL—Formulation 1
Ketoconazole Suspension 20 mg/mL—Formulation 2
Ketoprofen Suspension 20 mg/mL
Labetalol Hydrochloride Suspension 40 mg/mL—Formulation 1*
Labetalol Hydrochloride Suspension 40 mg/mL—Formulation 2
Labetalol Hydrochloride Syrup 10 mg/mL
Lamotrigine Suspension 1 mg/mL—Formulation 1
Lamotrigine Suspension 1 mg/mL—Formulation 2
Lansoprazole Solution 3 mg/mL*
Lansoprazole Suspension 3 mg/mL
Lapatinib Suspension 50 mg/mL
Lenalidomide Suspension 1.25 mg/mL
Losartan Suspension 2.5 mg/mL
Melatonin Suspension 1 mg/mL
Melatonin Suspension 3 mg/mL
Melatonin 1 mg/mL and Pyridoxine Hydrochloride 3.3 mg/mL Suspension
Methylcellulose Suspension 10 mg/mL (1%)
Methyldopa Syrup 50 mg/mL
Metolazone Suspension 1 mg/mL
Metoprolol Tartrate Suspension 10 mg/mL—Formulation 1*
Metoprolol Tartrate Suspension 10 mg/mL—Formulation 2
Metronidazole Suspension 10 mg/mL
Metronidazole Suspension 50 mg/mL*
Metronidazole Syrup 5 mg/mL—Formulation 1
Metronidazole Syrup 5 mg/mL—Formulation 2
Mexiletine Solution 10 mg/mL
Minocycline Hydrochloride Suspension 10 mg/mL
Minoxidil Suspension 1 mg/mL
Moxifloxacin Suspension 20 mg/mL
Naratriptan Hydrochloride Suspension 0.5 mg/mL
Nifedipine Solution 10 mg/mL
Nifedipine Suspension 1 mg/mL
Nifedipine Suspension 4 mg/mL—Formulation 1*
Nifedipine Suspension 4 mg/mL—Formulation 2
Olmesartan Medoxomil Suspension 2 mg/mL
Omeprazole Solution 2 mg/mL
Omeprazole Suspension 2 mg/mL
Oxandrolone Suspension 1 mg/mL
Oxandrolone Suspension 2 mg/mL
Oxandrolone Suspension 3 mg/mL
Pantoprazole Solution 2 mg/mL—Formulation 1
Pantoprazole Solution 2 mg/mL—Formulation 2
Penicillamine-D Suspension 50 mg/mL
Pentoxifylline Solution 20 mg/mL
Phenoxybenzamine Hydrochloride Solution 2 mg/mL
Procainamide Hydrochloride Suspension 50 mg/mL
Propylthiouracil Suspension 5 mg/mL—Formulation 1
Propylthiouracil Suspension 5 mg/mL—Formulation 2
Pyrazinamide Suspension 10 mg/mL
Pyrazinamide Suspension 100 mg/mL
Pyrazinamide Syrup 100 mg/mL*
Pyridoxine Hydrochloride Suspension 50 mg/mL
Pyrimethamine Suspension 2 mg/mL—Formulation 1
Pyrimethamine Suspension 2 mg/mL—Formulation 2
Quinapril Syrup 1 mg/mL
Quinidine Sulfate Suspension 10 mg/mL—Formulation 1
Quinidine Sulfate Suspension 10 mg/mL—Formulation 2
Riboflavin Suspension 10 mg/mL
Rifabutin Suspension 20 mg/mL
Rifampin Suspension 25 mg/mL—Formulation 1*
Rifampin Suspension 25 mg/mL—Formulation 2
Rifampin Syrup 10 mg/mL
Rifaximin Suspension 20 mg/mL
Rosuvastatin Suspension 4 mg/mL
Sodium Benzoate Syrup 250 mg/mL
Sodium Phenylbutyrate Suspension 200 mg/mL
Spironolactone 5 mg/mL and Hydrochlorothiazide 5 mg/mL Suspension—Formulation 1
Spironolactone 5 mg/mL and Hydrochlorothiazide 5 mg/mL Suspension—Formulation 2
Sulfadiazine Suspension 100 mg/mL
Sulfasalazine Suspension 100 mg/mL—Formulation 1
Sulfasalazine Suspension 100 mg/mL—Formulation 2
Sumatriptan Succinate Suspension 5 mg/mL
Sunitinib Malate Suspension 10 mg/mL
Tacrolimus Monohydrate Suspension 0.5 mg/mL
Tacrolimus Monohydrate Suspension 1 mg/mL
Tacrolimus Suspension 0.5 mg/mL
Tacrolimus Suspension 1 mg/mL*
Tadalafil Suspension 5 mg/mL
Temozolomide Suspension 10 mg/mL
Terbinafine Hydrochloride Suspension 25 mg/mL
Terbinafine Suspension 25 mg/mL
Terbutaline Sulfate Syrup 1 mg/mL
Tetracycline Hydrochloride Suspension 25 mg/mL—Formulation 1
Tetracycline Hydrochloride Suspension 25 mg/mL—Formulation 2
Thalidomide Suspension 20 mg/mL
Thiamine Suspension 100 mg/mL
Thioguanine Suspension 20 mg/mL*
Tiagabine Hydrochloride Suspension 1 mg/mL—Formulation 1
Tiagabine Hydrochloride Suspension 1 mg/mL—Formulation 2
Tinidazole Syrup 66.7 mg/mL
Topiramate Suspension 5 mg/mL
Tramadol Hydrochloride Suspension 5 mg/mL
Tramadol Hydrochloride Suspension 10 mg/mL
Tramadol Hydrochloride 7.5 mg/mL and Acetaminophen 65 mg/mL Suspension
Ursodiol Suspension 20 mg/mL
Ursodiol Suspension 25 mg/mL
Ursodiol Suspension 30 mg/mL
Ursodiol Suspension 50 mg/mL
Ursodiol Syrup 60 mg/mL—Formulation 1*
Ursodiol Syrup 60 mg/mL—Formulation 2*
Valacyclovir Hydrochloride Suspension 50 mg/mL*
Valsartan Suspension 4 mg/mL—Formulation 1
Valsartan Suspension 4 mg/mL—Formulation 2
Verapamil Hydrochloride Suspension 50 mg/mL
Ziprasidone Mesylate Syrup 2.5 mg/mL
Zonisamide Suspension 10 mg/mL—Formulation 1
Zonisamide Suspension 10 mg/mL—Formulation 2
Zonisamide Syrup 10 mg/mL*
Topical/Ophthalmic Solution
Show Items
Commercially Available Products (Use Only if Commercially Unavailable)
Show Items
Back Matter
Show Items
  • 1.

    General Chapter <795> Pharmaceutical Compounding—Nonsterile Preparations. In: United States Pharmacopeia and National Formulary (USP 43-NF 38). Revised January 1, 2014. Rockville, MD: The United States Pharmacopeia Convention Inc; 2020.

  • 1.

    Proposed Revisions to <795> Pharmaceutical Compounding – Nonsterile Preparations. The United States Pharmacopeia Convention Inc; 2021. Available at: https://go.usp.org/l/323321/2021-08-31/5kmcjf/323321/1630438802OI493yjz/BUD_Scientific_Rationale_for_the_2021_Proposed_Revisions_to__795_.docx. Accessed November 15, 2021.

  • 1.

    Pancorbo SA, Campagna KD, Devenport JK, et al.Task force report of competency statements for pharmacy practice. Am J Pharm Educ. 1987; 51:196–206.

    • Search Google Scholar
    • Export Citation
  • 2.

    Allen LV Jr. Establishing and marketing your extemporaneous compounding service. US Pharm. 1990; 15(Dec):74–7.

  • 3.

    Remington's pharmaceutical sciences. 18th ed. Gennaro AR, ed. Easton, PA: Mack Publishing; 1990; 1630–1, 1658, 1660.

  • 4.

    The United States Pharmacopeia, 22nd rev., and The National Formulary, 17th ed. Rockville, MD: The United States Pharmacopeial Convention; 1989.

    • Search Google Scholar
    • Export Citation
  • 5.

    USP DI Volume III: Approved drug products and legal requirements. 14th ed. Rockville, MD: The United States Pharmacopeial Convention; 1994.

    • Search Google Scholar
    • Export Citation
  • 6.

    USP DI Volume I: Drug information for the health care professional. 14th ed. Rockville, MD: The United States Pharmacopeial Convention; 1994.

    • Search Google Scholar
    • Export Citation
  • 7.

    29 §C.F.R. 1910. 1200(1990).

  • 8.

    ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990; 47:1033–49.

  • 9.

    Feinberg JL. Complying with OSHA's Hazard Communication Standard. Consult Pharm. 1991; 6:444, 446, 448.

  • 10.

    Myers CE. Applicability of OSHA Hazard Communication Standard to drug products. Am J Hosp Pharm. 1990; 47:1960–1.

  • 11.

    21 C.F.R. §211.137.

  • 12.

    Connors KA, Amidon GL, Stella VJ. Chemical stability of pharmaceuticals: a handbook for pharmacists. 2nd ed. New York: Wiley; 1986.

  • 13.

    American Society of Hospital Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm. 1993; 50:305–14.

    • Search Google Scholar
    • Export Citation
  • 14.

    Fitzgerald WL Jr. The legal authority to compound in pharmacy practice. Tenn Pharm. 1990; 26(Mar):21–2.

  • 1.

    Associated Press. Pittsburgh woman loses eye to tainted drugs; 12 hurt. Baltimore Sun. 1990; Nov 9:3A.

  • 2.

    Associated Press. Eye drop injuries prompt an FDA warning. N Y Times. 1990; 140(Dec 9):39I.

  • 3.

    Jeglum EL, Rosenberg SB, Benson WE. Preparation of intravitreal drug doses. Ophthalmic Surg. 1981; 12:355–9.

  • 4.

    Reynolds LA. Guidelines for preparation of sterile ophthalmic products. Am J Hosp Pharm. 1991; 48:2438–9.

  • 5.

    Reynolds LA, Closson R. Ophthalmic drug formulations. A handbook of extemporaneous products. Vancouver, WA: Applied Therapeutics; 1993.

  • 6.

    The United States Pharmacopeia, 22nd rev., and The National Formulary, 17th ed. Rockville, MD: The United States Pharmacopeial Convention; 1989:1692–3.

  • 7.

    Allen LV. Indomethacin 1% ophthalmic suspension. US Pharm. 1991; 16(May):82–3.

  • 8.

    American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990; 47:1033–49.

    • Search Google Scholar
    • Export Citation
  • 9.

    OSHA work-practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Am J Hosp Pharm. 1986; 43:1193–204.

  • 10.

    Ansel HC, Popovich NG. Pharmaceutical dosage forms and drug delivery systems. 5th ed. Philadelphia: Lea & Febiger; 1990:354–7.

  • 11.

    Stolar MH. Expiration dates of repackaged drug products. Am J Hosp Pharm. 1979; 36:170. Editorial.

  • 12.

    Remington's pharmaceutical sciences. 19th ed. Gennaro AR, ed. Easton, PA: Mack Publishing; 1990:1581–959.

Acetazolamide Suspension 25 mg/mL—Formulation 1

in Extemporaneous Formulations
DOI:
https://doi.org/10.37573/9781585286522.001
Free access

INGREDIENTS:

Acetazolamide 250 mg tablet 12 tablets
Ora-Plus/Ora-Sweet* QSAD: 120 mL

EQUIPMENT AND SUPPLIES:

Powder containment hood, mortar and pestle, graduated cylinder

PREPARATION DETAILS:

  1. Triturate tablets to a fine powder with a mortar and pestle.

  2. Levigate powder with a small amount of vehicle to form a paste.

  3. Add vehicle in increasing amounts while mixing thoroughly.

  4. Transfer contents of the mortar to a graduated cylinder.

  5. Rinse the mortar and pestle with vehicle and pour into graduated cylinder.

  6. Add vehicle to the graduated cylinder to achieve the total volume indicated above.

  7. Transfer contents of the graduated cylinder into an appropriately sized amber bottle.

  8. Shake well to mix.

Special Instructions — *Mix 60 mL of Ora-Plus with 60 mL of Ora-Sweet. Use mixture as vehicle or use Ora-Blend.

Alternatives — May substitute vehicle with cherry syrup (cherry syrup concentrate diluted 1:4 with simple syrup) or 60 mL of Ora-Plus mixed with 60 mL of Ora-Sweet SF or Ora-Blend SF.

Quality-Control Procedures — Visually inspect for physical appearance of formulation and container closure integrity (no leakage, cracks in container, or improper seals).

Labeling Requirements — Extemporaneously compounded preparation. For oral use only. Store at room temperature or refrigerate. Shake well before use.

Storage Conditions/Stability — Store at room temperature or refrigerate. Stable for 60 days.

STABILITY STUDY DETAILS:

Study Container Type — Amber clear plastic (polyethylene terephthalate [PET]) prescription ovals with a low-density polyethylene foam cap lining

Referenced Manufacturers — Acetazolamide tablets (Mutual Pharmaceutical Co, Inc); Ora-Plus, Ora-Sweet, Ora-Sweet SF (Paddock Laboratories, LLC); cherry syrup concentrate (Robinson Laboratories, Inc); simple syrup (not specified).

Stability-Indicating Study — Yes

REFERENCE

1.

Allen LV Jr, Erickson MA 3rd. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. Am J Health Syst Pharm. 1996;53(16):1944–1949.

  • Search Google Scholar
  • Export Citation